

### 1.3.1.1 PROFESSIONAL INFORMATION FOR MEDICINES FOR HUMAN USE

#### SCHEDULING STATUS

**S3**

#### 1. NAME OF THE MEDICINE

**PANAMOR EYE DROPS** 1 mg/ml ophthalmic solution

#### 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 1 ml of PANAMOR EYE DROPS contains 1 mg diclofenac sodium.

Preservative: Sorbic acid 0,2 % *m/v*

For full list of excipients, see section 6.1.

#### 3. PHARMACEUTICAL FORM

Ophthalmic solution.

PANAMOR EYE DROPS is a colourless to pale yellow solution. Free from visible particles.

#### 4. CLINICAL PARTICULARS

##### 4.1. Therapeutic indications

PANAMOR EYE DROPS is indicated for:

- The alleviation of post-operative inflammation of the anterior segment in cataract surgery.
- Short term use for ocular surface pain from corneal origin.
- Short term use for inflammation following argon laser trabeculoplasty. Safety and efficacy of treatment for inflammation following argon laser trabeculoplasty for more than 4 days have not been established.

## **4.2. Posology and method of administration**

### **Posology**

#### *Adults*

The dose is governed by the severity of the condition.

Pre-operatively: up to 5 drops during 3 hours before surgery.

Post-operatively: 3 drops after surgery. Thereafter, instil one drop into the conjunctival sac, 4 to 5 times daily.

Other indications: 1 drop 4 to 5 times daily depending on the severity of the condition.

### **Paediatric population**

The use of PANAMOR EYE DROPS has not been studied in young children.

### **Method of administration**

Instillation into the conjunctival sac (see section 4.4).

## **4.3. Contraindications**

PANAMOR EYE DROPS is contraindicated in:

- Patients with hypersensitivity to diclofenac sodium or to any excipients in PANAMOR EYE DROPS (see section 6.1).
- In patients wearing soft contact lenses.
- In patients hypersensitive to aspirin, NSAIDs or other prostaglandin synthetase inhibitors.

- In patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or by other medicines with prostaglandin synthetase inhibiting activity.
- In young children.
- Intraocular use of PANAMOR EYE DROPS during surgical procedures.
- In patients with heart failure, established ischaemic heart disease and/or cerebrovascular disease (stroke) and peripheral arterial disease.
- In patients with a history of gastrointestinal perforation, ulceration or bleeding (PUBs) related to previous NSAIDs, including PANAMOR EYE DROPS.
- In patients with an active or a history of recurrent ulcer/ haemorrhage/ perforations.
- Lactation (see section 4.6).
- Pregnant women from around 20 weeks of gestation or later in pregnancy (see section 4.4 and 4.6).

#### **4.4. Special warnings and precautions for use**

##### *Ocular effects*

Diclofenac, as in PANAMOR EYE DROPS, has been implicated in reports of corneal toxicity. Ulceration of the conjunctiva or cornea, corneal or scleral melts and perforations have been reported, particularly after cataract surgery.

Caution is advised in patients with risk factors to corneal ulceration and thinning, such as with corticosteroid use or with concomitant diseases, such as infections or rheumatoid arthritis.

Diclofenac sodium, as in PANAMOR EYE DROPS, has been associated with corneal ulcer or thinning. Most patients were treated for a prolonged period of time.

Following instillation of PANAMOR EYE DROPS, nasolacrimal occlusion or closing the eyes for 3 minutes may reduce the systemic absorption. This may result in a decrease in systemic side effects and an increase in local activity.

An interval of at least five minutes between the application of PANAMOR EYE DROPS and the different medicines must be allowed.

The anti-inflammatory action of PANAMOR EYE DROPS may mask the onset and/or progression of ocular infections.

In the presence of infection, or if there is a risk of infection, appropriate therapy should be given concurrently with PANAMOR EYE DROPS.

#### *Haematological effects*

With some non-steroidal anti-inflammatory medicines (NSAIDs), there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied non-steroidal anti-inflammatory medicines (of which class PANAMOR EYE DROPS belongs to), may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery.

It is recommended that PANAMOR EYE DROPS be used with caution in patients with known haemostatic defects or bleeding tendencies, or who are receiving other medicines which may prolong bleeding time (see section 4.5).

#### *Use with topical steroids*

Caution should be exercised when topical NSAIDs such as diclofenac, as in PANAMOR EYE DROPS, are used concomitantly with topical steroids (see section 4.5).

#### *Cardiovascular effects*

Caution is required in patients with a history of hypertension and/or heart failure as fluid retention and oedema have been reported in association with diclofenac sodium, as in PANAMOR EYE DROPS therapy. In view of PANAMOR EYE DROPS inherent potential to cause fluid retention, heart failure may be precipitated in some compromised patients.

Caution is required in patients with significant risk factors for cardiovascular events (e.g., hypertension, hyperlipidaemia, diabetes mellitus, smoking).

#### *Gastrointestinal effects*

The risk of gastrointestinal perforation, ulceration or bleeding (PUBs) is higher with increasing doses of PANAMOR EYE DROPS, in patients with a history of ulcers, and the elderly.

When gastrointestinal bleeding or ulceration occurs in patients receiving PANAMOR EYE DROPS, treatment with PANAMOR EYE DROPS should be stopped.

PANAMOR EYE DROPS should be given with caution to patients with a history of gastrointestinal disease (e.g., ulcerative colitis, Crohn's disease, hiatus hernia, gastro-oesophageal reflux disease, angiodysplasia) as the condition may be exacerbated.

#### *Elderly*

The elderly has an increased frequency of adverse reactions to NSAIDs including diclofenac sodium, as in PANAMOR EYE DROPS, especially gastrointestinal perforation, ulceration and bleeding (PUBs) which may be fatal.

#### *Skin reactions*

##### *Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis*

Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and Toxic Epidermal Necrolysis (TEN) have been reported. PANAMOR EYE DROPS should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.

#### *Drug reaction with eosinophilia and systemic symptoms*

Drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported in patients taking NSAIDs such as PANAMOR EYE DROPS. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling. Other clinical manifestations may include hepatitis, nephritis, haematological abnormalities, myocarditis, or myositis.

Sometimes symptoms of DRESS may resemble an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its presentation, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, discontinue PANAMOR EYE DROPS and evaluate the patient immediately.

#### *Use in pregnancy*

It is recommended that PANAMOR EYE DROPS be avoided in pregnant women at 20 weeks or later in pregnancy (see section 4.3 and 4.6).

The use of NSAIDs, such as diclofenac sodium, as in PANAMOR EYE DROPS, around 20 weeks gestation or later in pregnancy may cause foetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may include limb contractures and delayed lung maturation. In some post marketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required.

Healthcare professionals should consider ultrasound monitoring of amniotic fluid if PANAMOR EYE DROPS treatment extends beyond 48 hours. Discontinue PANAMOR

EYE DROPS if oligohydramnios occurs and follow up according to clinical practice.

### **Paediatric population**

The use of PANAMOR EYE DROPS has not been studied in young children.

#### *Excipients*

PANAMOR EYE DROPS contains boric acid which may be harmful in children.

## **4.5. Interaction with other medicines and other forms of interaction**

### *Topical steroids*

Concomitant use of PANAMOR EYE DROPS and topical steroids in patients with significant pre-existing corneal inflammation may increase the risk of developing corneal complications, therefore caution should be used (see section 4.4).

All topical NSAIDs, such as PANAMOR EYE DROPS, may slow or delay healing. Topical corticosteroids may also slow or delay healing. Concomitant use of PANAMOR EYE DROPS together with a topical steroid may increase the potential for healing problems.

### *Other NSAIDs*

Use of two or more NSAIDs, such as PANAMOR EYE DROPS, concomitantly could result in an increase in side effects.

### *Corticosteroids*

Increased risk of gastrointestinal perforation, ulceration or bleeding (PUBs).

### *Anti-coagulants*

PANAMOR EYE DROPS may enhance the effects of anti-coagulants such as warfarin.

#### *Anti-platelet medicines*

Increased risk of gastrointestinal bleeding.

It is recommended that PANAMOR EYE DROPS be used with caution in patients with known bleeding tendencies or who are receiving other medicines which may prolong bleeding time (see section 4.4).

#### *Acetylcholine and carbachol ophthalmic preparations*

There have been reports that acetylcholine and carbachol ophthalmic preparations have been ineffective when used in patients treated with ophthalmic NSAIDs, such as PANAMOR EYE DROPS.

#### *Selective serotonin reuptake inhibitors (SSRIs)*

Increased risk of gastrointestinal bleeding.

### **4.6. Fertility, pregnancy and lactation**

#### **Pregnancy**

It is recommended that PANAMOR EYE DROPS is avoided in pregnant women at 20 weeks or later in pregnancy (see section 4.3 and 4.4).

#### **Breastfeeding**

Diclofenac, as in PANAMOR EYE DROPS, is excreted in breastmilk. However, at therapeutic doses of PANAMOR EYE DROPS no effects on the suckling child are anticipated. Use of PANAMOR EYE DROPS is not recommended during breastfeeding (see section 4.3).

#### **Fertility**

There is no data available regarding PANAMOR EYE DROPS and fertility.

#### 4.7. Effects on ability to drive and use machines

PANAMOR EYE DROPS has minor influence on the ability to drive or use machines.

Since adverse reactions such as blurred vision and other ocular reactions have been reported in patients receiving PANAMOR EYE DROPS, patients should not drive, use machinery or perform any tasks that require concentration, until they are certain that PANAMOR EYE DROPS does not adversely affect their ability to do so (see section 4.4).

#### 4.8. Undesirable effects

##### a) Summary of the safety profile

The most frequently observed adverse events for NSAIDs, such as diclofenac sodium, as in PANAMOR EYE DROPS, are gastrointestinal in nature.

##### b) Tabulated list of adverse reactions

System organ class	Frequent	Less frequent	Frequency unknown (cannot be estimated from the available data)
<b>Immune system disorders</b>			Systemic hypersensitivity reactions such as urticaria, rash, eczema, erythema, pruritus, cough, rhinitis.
<b>Eye disorders</b>	Mild transient burning sensation and stinging,	Hypersensitivity reactions with eye itching, reddening, photosensitivity, ocular hyperaemia, blurred vision immediately after installation of the eye drop.	Ulceration of the conjunctiva or cornea, corneal or sclera melts and perforations,  corneal disorders, punctuate keratitis,

	transient eye pain, mild to moderate eye irritation.		corneal thinning, corneal epithelium defect, corneal oedema,  allergic conditions for ocular reactions such as conjunctival hyperaemia, allergic conjunctivitis, eyelid erythema, oedema and pruritus.
<b>Cardiac disorders</b>			Oedema, hypertension, cardiac failure.
<b>Respiratory, thoracic and mediastinal disorders</b>		Dyspnoea, exacerbation of asthma.	
<b>Gastrointestinal disorders</b>	Peptic ulcers, perforation or gastrointestinal bleeding, sometimes fatal; nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease, gastritis.		
<b>Skin and subcutaneous tissue disorders</b>			Bullous reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) (see section 4.4).

*c) Description of selected adverse reactions*

*Eye disorders*

Punctate keratitis or corneal disorders have been observed, usually after frequent application. In patients with risk factors of corneal disorders such as during the use of corticosteroids or with concomitant diseases such as infections or rheumatoid arthritis, diclofenac, as in PANAMOR EYE DROPS, has been associated with ulcerative keratitis, corneal thinning, punctuate keratitis, corneal epithelium defect and corneal oedema, which

might become sight-threatening. Patients were treated for a prolonged period of time (see section 4.4).

#### *Reporting of suspected adverse reactions*

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare providers are asked to report any suspected adverse reactions to:

**SAHPRA:** <https://www.sahpra.org.za/health-products-vigilance/>

#### **Aspen Pharmacare:**

**E-mail:** [Drugsafety@aspenpharma.com](mailto:Drugsafety@aspenpharma.com)

**Tel:** 0800 118 088

### **4.9. Overdose**

#### **Symptoms**

Overdosage will not ordinarily cause acute problems.

There is practically no risk of adverse effects due to accidental oral ingestion, since a 5 ml bottle of PANAMOR EYE DROPS contains only 5 mg of diclofenac sodium, corresponding to about 3 % of the recommended maximum daily adult dose of diclofenac sodium after oral administration. By way of comparison, the maximum oral daily dose for diclofenac sodium recommended in children is 2 mg/kg body weight.

#### **Treatment**

If PANAMOR EYE DROPS are accidentally ingested, fluids should be taken to dilute the medicine. Treatment is supportive and symptomatic.

## **5. PHARMACOLOGICAL PROPERTIES**

### **5.1. Pharmacodynamic properties**

Category and Class: A 15.4 Ophthalmic preparations: Other

Pharmacotherapeutic group: Anti-inflammatory agents, non-steroids

ATC code: S01BC03

#### *Mechanism of action*

Diclofenac sodium is an enzyme inhibitor in the biosynthesis of prostaglandins. As such it has anti-inflammatory and analgesic properties. Topical diclofenac penetrates the anterior chamber in the human eye.

Diclofenac reduces inflammatory reactions of the anterior ocular segments caused by mechanical and allergic factors. The miosis induced by surgical trauma is inhibited by diclofenac. Re-epithelialisation of the cornea is apparently not inhibited by local diclofenac action.

Animal studies have demonstrated sodium diclofenac's ability to reduce leucocyte accumulation and exudation into the chamber fluid after attack on the anterior chamber of the eye.

### **5.2. Pharmacokinetic properties**

#### **Absorption and distribution**

Plasma levels of diclofenac, following ocular instillation of two drops into each eye over a 4 hour period were below the limit of quantification, suggesting limited systemic absorption.

The onset of action is rapid and lasts several hours.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1. List of excipients**

Boric acid, edetate disodium, polyoxyl 35 castor oil, sorbic acid

## **6.2. Incompatibilities**

Not applicable.

## **6.3. Shelf life**

24 months

## **6.4. Special precautions for storage**

Store at or below 25 °C.

Discard 30 days after opening.

Protect from light. Do not freeze.

Keep in original packaging until required for use.

## **6.5. Nature and contents of container**

2,5 ml or 5 ml is packed in a white opaque low density polyethylene bottle with a translucent low density polyethylene nozzle and a white high density polyethylene cap with tear off ring. The bottle is packed in an outer cardboard carton together with a leaflet.

Not all packs and pack sizes are necessarily marketed.

## **6.6 Special precautions for disposal and other handling**

No special requirements.

## **7. HOLDER OF CERTIFICATE OF REGISTRATION**

PHARMACARE LIMITED

Healthcare Park

Woodlands Drive

Woodmead 2191

## **8. REGISTRATION NUMBER**

45/15.4/0686

## **9. DATE OF FIRST AUTHORISATION**

11 June 2015

## **10. DATE OF REVISION OF TEXT**

02 November 2021

Die Afrikaanse Professionele Inligting is op versoek beskikbaar.

Mediese Blitslyn: 0800 118 088.

ZA\_PANAEDP\_2111\_00